论文部分内容阅读
目的:观察羧甲司坦治疗稳定期慢性阻塞性肺疾病(COPD)患者的临床疗效。方法:88例稳定期COPD患者随机分为观察组和对照组各44例,对照组予常规治疗,治疗组在对照组基础上加用羧甲司坦片0.5 g,po,tid。治疗6个月后测定两组肺功能、Borg呼吸困难评分、6 min步行距离(6MWT),统计沙丁胺醇使用次数及急性加重发作次数,进行圣乔治呼吸问题调查问卷(SGRQ);记录不良反应。结果:治疗后,治疗组6MWT明显延长,Borg评分显著下降;使用沙丁胺醇(17.1±5.8)次,急性发作(0.4±0.2)次;生活质量评分显著提高,各项指标均明显优于对照组(P<0.05或0.01)。两组治疗过程中均无明显不适出现。结论:长期服用羧甲司坦可明显提高稳定期COPD患者的运动能力,改善呼吸困难及生活质量。
Objective: To observe the clinical efficacy of carbetolide in patients with stable chronic obstructive pulmonary disease (COPD). Methods: A total of 88 patients with stable COPD were randomly divided into observation group (44 cases) and control group (44 cases). The control group was given routine treatment. The treatment group was treated with carbocisteine 0.5 g, po, tid. Six months after the treatment, the lung function, Borg dyspnea score, 6-minute walk distance (6MWT), statistical frequency of albuterol use and the number of acute exacerbation seizures were used to investigate the St. George’s Respiratory Questionnaire (SGRQ). Adverse reactions were recorded. Results: After treatment, 6MWT in treatment group was significantly prolonged and Borg score was significantly decreased. Salbutamol (17.1 ± 5.8) times and acute attack (0.4 ± 0.2) times were used in the treatment group, and the quality of life scores were significantly improved. All indexes were significantly better than those in the control group P <0.05 or 0.01). No significant discomfort occurred during the treatment of both groups. CONCLUSION: Long-term use of carbocisteine significantly improves exercise capacity and improves dyspnea and quality of life in patients with stable COPD.